Treatment of embryonal tumors (ET) is a challenge for the pediatric oncologist. Innovative translational research is required to exploit available genomic data and implement state-of-the-art technologies to overcome the deficits of current diagnostic and treatment strategies. We will set up a consortium of leading European institutions and SMEs with extensive clinical and technological expertise to establish a unique pipeline for the comprehensive development and validation of novel diagnostic tools in addition to efficient preclinical drug development for ET.